Mucosal vaccination offers great advantage for inducing protective immune response at the sites of viral transmission. A novel replication-competent modified vaccinia Tian Tan (MVTT) is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of people in China. MVTT was generated through genetic engineering and clonal selection of VTT and exhibited excellent safety profiles for mucosal inoculation. The spike glycoprotein (S) of SARS-CoV was used as a test antigen after the S gene was constructed in the identical genomic location of two live vectors to generate vaccine candidates MVTT-S and MVA-S. A head-to-head comparison has been conducted in mice for inducing neutralizing antibodies (Nabs) via mucosal vaccination. Our results indicated that MVTT is superior to MVA for inducing high levels of systemic Nab response post mucosal vaccination. Moreover, a candidate vaccine MVTT-SIVgpe, which expresses three major viral structural proteins of simian immunodeficiency virus, has been recently characterized in vitro. The efficacy of MVTT-SIVgpe will be further evaluated in a highly pathogenic SIV/Chinese macaque model. Hepatitis B virus (HBV) infection is the commonest cause of hepatocellular carcinoma (HCC) most countries in Asia. After the launching of the universal vaccination program, the incidence of childhood HCC has been dramatically reduced in Taiwan. As HCC in adult commonly develop at the age the 40 to 50 years, it may take another 20 to 30 years before one can see a significant reduction in incidence of adult HCC. Clearance of HBsAg is the marker of ultimate viral control in chronic hepatitis B. If HBsAg clearance occurs before the age of 50, the prognosis is excellent. However, spontaneous HBsAg clearance is rare. Peginterferon and oral antiviral agents can induce HBsAg clearance in about 10% and 5% of patients, respectively. High HBV DNA has been found to associate with higher risk of HCC. However the data from individual studies on the long term benefit of interferon or antiviral agent is conflicting. A meta-analysis has been conducted to investigate the beneficial effect of interferon and antiviral agents (mainly lamivudine) on HCC. Interferon is associated with an approximate 33% reduction in risk of HCC. Lamivudine is associated with an approximate 80% reduction in risk of HCC. In summary, vaccination can prevent HCC by preventing HBV infection. HBsAg clearance in an early age can almost prevent HCC. Interferon and antiviral treatment can reduce the risk but not completely prevent HCC.
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CS15-02 Current Japanese Strategies for Preventing HCC Development
Yoshiyuki Ueno *. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
In Japan, the death caused by liver disease is still major problems in health care. Most importantly, the death from liver diseases exceeds 30,000 cases in Japan. Approximately, nearly 80% of these death is derived from hepatitis C virus (HCV) related liver diseases, namely hepatocellular carcinoma (HCC). Although the incident of HCV infections is decreasing in Japan due to current screening strategies, the patients with established infections have reached their most susceptible stage for developing HCC. In other words, the Japanese patients with HCV infection are facing highest risk for developing HCC. The current preventive strategies for developing HCC includes antiviral therapy, namely interferon based regimen. However, the results of current standard therapy, PEG-interferon plus ribavirin treatment, is not satisfactory in genotype 1b with high viral load, which is most commonly observed population in Japan and US. The recent reports have documented up to 50% of the patients treated with antiviral therapy eradicated HCV genotype 1b infection. Moreover, the adherence to the antiviral therapy is poorly tolerated in elderly populations, which is now biggest patients' population in Japan. Thus, in Japanese society, the eradication of HCV itself seems more and more difficult. Moreover, the social benefit regarding antiviral treatment in elderly patients, especially above 70 years old, has not been established. The patients in this age have the highest risk for developing HCC and poorest results after antiviral treatment. Furthermore, these patients tend to be intolerant to the interferon based treatment. Adverse effects such as depression are more commonly observed in these elderly patients. Besides these anti-viral treatments, so-called maintenance therapies are frequently applied to these elderly populations. Low-dose interferon monotherapy, oral intake of ursodeoxy cholic acids, and phlebotomy are included in these maintenance therapies. However, the recent results from HALT-C gave questions about the rational of long-term interferon monotherapy. Thus, the evidences for preventing HCCs by these maintenance therapies seem to be weak. In summary, the Japanese strategies for preventing HCC development is; i) eradicate the possible as early as possible since the adherence to the standard antiviral treatment is poor in elderly patients with HCV, ii) perform social education for understanding the natural course of HCV infection to accept the early eradicative treatment, iii) establish the social supportive program to receive antiviral therapy (both medical and economical), and iv) develop interferon free based antiviral treatment to increase the adherence of antiviral therapy in elderly populations.
CS15-03 Prevention of HCC Related to Viral Hepatitis
Jun Cheng *. Beijing Ditan Hospital, Beijing, China
CS15-04 The Role of Polo-like Kinase 1 as a Therapeutic Target in Hepatocellular Carcinoma
Seng-Gee Lim *. National University Health System, Singapore
Polo-like kinase 1 (PLK1) plays important roles in the progression of cell cycle, especially for cells transiting from anaphase to telophase during mitosis. PLK1 has been found to be overexpressed in various cancers, and has important prognostic implications. Methods: PLK1 gene expression was evaluated in Hepatocellular carcinoma (HCC) and found to be overexpressed frequently in HCC tissues. Gene silencing technology utilizing short interfering RNA (siRNA) was subsequently employed to study the potential of PLK1 to be the therapeutic target in treating HCC. Knockdown with si-RNA was performed to examine for reduction in cell proliferation using MTS and BrdU assays, after validating reduced expression by real-time PCR (RTPCR) and Western Blotting. Confirmation of apoptosis was performed using TUNEL assay, and subsequent pathway of apoptosis was examined using a caspaseinhibition assay. Experiments with transplanted tumour cell lines into nude mice co-cultured with si-RNA against the target gene, and examining for reduced tumour progression compared to controls was performed. Results: Microarray analysis showed the most common over-expressed gene was PLK1 by 12 times, and was also found to be over-expressed in Huh-7 cells. SiRNA against PLK-1 validated by real-time PCR (RTPCR) and Western Blotting showed a reduction of PLKR1 expression up to 96% in huh-7 cells, and reduced cell proliferation by 68% and 92% in MTS and BrdU cell proliferation assays respectively. There was 3-fold increase in apoptosis events, and TUNEL staining and caspase-3 assays suggested that this may be caspase-independent. The pan-caspase inhibitor Z-VAD-FMK was unable to rescue apoptotic cells. Immnofluorescence studies co-localised endonuclease G to fragmented chromosomes, thus was postulated to be the main apoptotic effector. Knockdown of the FOXM1 transcription factor, thought to be a positive regulating factor did not affect PLK1 gene expression, suggesting other transcription factors may be important. Finally, huh-7 cells transplanted subcutaneously into nude mice using matrigel were treated with si-PLK1 and control si-RNA. Tumour regression of 33% occurred in the mice treated with si-PLK1 but not in controls. Conclusion: PLK1 overexpression in HCC was shown to be functionally important by gene silencing experiments, and may be a potential therapeutic target.
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CS16-01 A Work in Progress: MRSA and cMRSA in Latin America
Raul E. Isturiz *.
Department of Medicine, Infectious Diseases, Centro Medico de Caracas, Caracas, Venezuela
MRSA is the leading cause of nosocomial infection in Latin America, and the number of reports of community-acquired (cMRSA) infections continue to rise. The full extent of the problem is unknown because surveillance information is only available from large hospitals, while much of the population is cared for in small centers that do not perform microbiological testing or use different methodology and definitions. Under these conditions, monitoring the epidemiology of MRSA remains a challenge and there is a need to improve detection and management.
Nosocomial, multidrug-resistant MRSA is a growing problem in Latin America with estimated prevalence for the region currently near or above 50% for non blood stream infections and over 40% for bacteremia. Reports of CA-MRSA infections initially came from Brazil in 2003. Soon, a large outbreak of CA-MRSA infection that affected inmates in jails and people from the community in Uruguay was described; more than 1000 patients were affected and 12 died. In the region SSTIs account for the majority of cases, but severe forms of pneumonia were reported, including 4 deaths. In this outbreak, TMP-SMX remains active in vitro and is used for the treatment of skin infections. Interestingly, an apparent decrease in MRSA strains with vancomycin MIC greater or equal to 1 μg/ml suggests a shift in clonal dissemination, and further data are required to follow this trend, which may have important implications for treatment. Although surveillance systems in Latin America are improving, many limitations remain. With advances in sequencing technology, the evolutionary history of the MRSA clone ST5 was further studied by mutation discovery at 108 loci (46kb) within a global collection. Sequence polymorphisms in 1.6% (46,483 bp) of the genome from each MRSA strain was screened. The SNPS defined a radial phylogenetic structure within ST5 consisting of at least 5 chains of mutational steps that define geographically associated clades. Mapping of the independent imports of the SCCmec demonstrated import occurred at least 23 occasions, and that the progeny of such recombinant strains are locally rather than globally. This further exemplifies that geographical spread of MRSA over long distances and across cultural borders is a rare event compared with the frequency with which SCCmec has been imported.
CS16-03 Molecular Characteristic of Community-Acquired, Methicillin-Resistant
Staphylococcus aureus
Xuzhuang Shen *. Education Department, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing, China MRSA became the most common nosocomial pathogen in many hospitals since the 1980s, especially in many Asian countries. Epidemiologic reports showed that >50% of S. aureus isolates from the hospitals in Korea, Japan, Taiwan, Hong Kong, Singapore, and Sri Lanka were MRSA. MRSA infection is now increasingly reported in the community. According to the ANSORP study from 2004 to 2006 in 9 Asian countries, the prevalence of MRSA among community-associated S. aureus isolates was 20.8% in Asian region and it was the highest in Taiwan (40.5%), followed by Sri Lanka (38.8%), the Philippines (30.1%), and Vietnam (28.2%). Skin and soft tissue infection was the most common infection by community-associated MRSA (CA-MRSA) followed by respiratory tract infection and primary bacteremia. CA-MRSA isolates from Asian region showed diverse microbiologic and genetic features
